Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes

By In The News
April 28, 2019 in The Headlines

Recommended Posts

In The News

Posted April 28, 2019

- Share

Posted April 28, 2019

BALTIMORE, April 28, 2019 /PRNewswire/ -- Novo Nordisk today announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza® (liraglutide) injection 1.8 mg vs placebo in reducing blood sugar in children and adolescents aged 10-17...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222008
2. Jaydee
  17783
3. deicer
  13345
4. Kip Powick
  12311
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.4k
- Total Posts
  
  565k

Sign In

Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support